Navigation Links
New Interim Data About Combination Oral Contraceptives
Date:3/25/2011

sion to implement a pause in their COC routine."  

Following the submission of the interim analysis, Bayer worked with the US Food and Drug Administration (FDA) and updated the Prescribing Information for YAZ® (3 mg drospirenone / 0.02 mg ethinyl estradiol) in the US.  Bayer will continue to work with the FDA to update the Prescribing Information for all of its oral contraceptives in the US.

Like pregnancy, the use of COCs is associated with an increased risk of blood clots, which can be life-threatening. However, pregnancy increases the risk of blood clots as much or more than the use of COCs. These events are uncommon in healthy women using COCs.

Since 2001, Bayer commissioned independent investigators to conduct large-scale observational studies assessing the risk of VTE in women using COCs containing a variety of progestins, including drospirenone.  The results from these studies have been shared with the FDA and other regulatory authorities.

"Increased VTE risk is associated with any COC, and Bayer is committed to studying the safety and efficacy of our products.   Birth control pills are among the most systematically studied medicines available today," said Dr. Plouffe.

Several studies have investigated the relative risks of thromboembolism in women using drospirenone-containing COCs compared to women using COCs containing other progestins.

Bayer's post-marketing studies have shown that the risk of VTE in a COC formulation containing 3 mg drospirenone in combination with 0.03 mg ethinyl estradiol is comparable to that of any COCs in those studies.(1,2)

Two other published studies – one case-control study and one retrospective cohort study – have suggested that the risk of VTE occurring in drospirenone/ethinyl estradiol users was between the risk associated with levonorgestrel-containing COCs and desogestrel/gestodene-containing COCs.(3,4)  In April 2010, the FDA appro
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
(Date:12/22/2014)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, announced today that the first cohort ... and pharmacodynamic study with d-Methadone, the company,s N-methyl-D-aspartate ... Racemic methadone is a long-acting opioid used in ... therapy in opioid addiction.  It is constituted by ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... Isotopes Inc (OTC Bulletin Board: INIS ) announces ... general business status, particularly, the year to date performance of ... of its ongoing plans for the depleted uranium de-conversion project. ... When: Wednesday, September 14 – 3:00PM ...
... 2011 The Educational Review System announces the pediatric ... Gaps — Where do we go from here?" – ... first annual Pediatric Medication Safety Summit, will focus on ... benefits of technology and the gaps. ...
Cached Medicine Technology:International Isotopes Inc Announces Conference Call to Give an Update on the Company's General Business Status 2
(Date:12/22/2014)... 2014 The Bob Woodruff Foundation ... invested more than $5 million in programs and ... their families. , This includes $1.3 million in ... helping with: veteran entrepreneurship; community impact; vocational training; ... severely injured veterans. , “The needs of those ...
(Date:12/22/2014)... Give a loved one the greatest gift ... and vitality. , For a limited time, HealthiPlus ( ... in special Holiday Wellness gift packages at drastically reduced ... bottle contains cutting-edge, proven nutritional support for joints, mental ... as we age. , Joint Health Plus ...
(Date:12/22/2014)... 2014 Xarelto Lawsuit News : ... judges has granted a request to centralize pending and ... Court, Eastern District of Louisiana. The U.S. Judicial Panel ... 12 to transfer over 50 Xarelto cases–21 lawsuits and ... Louisiana court for consolidation under U.S. District Judge Eldon ...
(Date:12/22/2014)... 2014 Christmas is days away, and last ... and easy solution that will please: the Sublime Gift ... from from $25 up to $350," says Kathy Heshelow, founder ... and a wide array of skin care products and Skin ... expiration dates. , Gift delivery past shipping deadlines, or ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
Breaking Medicine News(10 mins):Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3
... Once-daily Keppra XR(TM) (levetiracetam) extended-release tablets are now ... to simplify patients, treatment plans by decreasing the ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090410/NY97244 )According to studies published ... Neurology , patients are more likely to adhere ...
... Tenn., April 10 ProLogis (NYSE: PLD ... today that it has leased approximately 211,000 square feet ... global provider of products and services that improve the ... the space at ProLogis Park DeSoto, a master-planned distribution ...
... Dr. Ashish K. Jha of the Harvard School of Public Health ... ... Washington, DC (PRWEB) April 10, 2009 -- Leroy Jones, ... Washington, D.C., has recorded another episode of his podcast series, "Talking ...
... sport-specific eyewear to prevent devastating injuriesAUSTIN, Texas, April 9 ... routine basketball game his senior year of high school turned ... who played years of hoops without any injuries. But when ... Stephen ended up with a large laceration on his left ...
... LLP, a San Francisco, California-based trial law firm, filed the first ... Raptiva medication. Filed in Alameda Superior Court, the complaint seeks ... ... (PRWEB) April 9, 2009 -- Audet & Partners, LLP , ...
... one of 14 given recent warning, will remain on the ... Bowing to the pleas of hospice experts, the U.S. Food ... from the market an unapproved liquid morphine painkiller given to ... the FDA,s Center for Drug Evaluation and Research, told the ...
Cached Medicine News:Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 2Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 3Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 4Health News:ProLogis Leases 211,000 Square Feet to Cardinal Health Near Memphis 2Health News:New Interview on E-Health Records with Dr. Ashish K. Jha of the Harvard School of Public Health on Talking Technology 2Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Audet & Partners, LLP Files First Raptiva Lawsuit After Announced Withdrawal 2Health News:Audet & Partners, LLP Files First Raptiva Lawsuit After Announced Withdrawal 3Health News:FDA Reverses Stance on Removal of Morphine Painkiller 2
Cytomegalovirus IgM ELISA....
Small Incision Microforceps: Tano ILM Forceps...
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Microforceps: Claes ILM Forceps...
Medicine Products: